Trial Profile
Prospective Registry of rivaroxaban management of cancer-associated venous thromboembolism study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms PRIMECAST
- 24 May 2022 Status changed from recruiting to active, no longer recruiting.
- 20 May 2019 Status changed from not yet recruiting to recruiting.
- 23 Nov 2018 New trial record